As of 2025-11-06, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -2.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 127.63 mil USD. SGMO's TTM EBITDA according to its financial statements is -62.02 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 15.6x | 15.3x |
| Forward P/E multiples | 21.5x - 51.3x | 36.4x |
| Fair Price | (4.29) - (3.08) | (5.19) |
| Upside | -880.3% - -659.8% | -1042.8% |
| Date | EV/EBITDA |
| 2025-11-05 | -2.06 |
| 2025-11-04 | -2.11 |
| 2025-11-03 | -2.20 |
| 2025-10-31 | -2.29 |
| 2025-10-30 | -2.16 |
| 2025-10-29 | -2.20 |
| 2025-10-28 | -2.25 |
| 2025-10-27 | -2.44 |
| 2025-10-24 | -2.46 |
| 2025-10-23 | -2.58 |
| 2025-10-22 | -2.59 |
| 2025-10-21 | -2.52 |
| 2025-10-20 | -2.67 |
| 2025-10-17 | -2.49 |
| 2025-10-16 | -2.52 |
| 2025-10-15 | -2.74 |
| 2025-10-14 | -2.72 |
| 2025-10-13 | -2.67 |
| 2025-10-10 | -2.65 |
| 2025-10-09 | -2.98 |
| 2025-10-08 | -2.75 |
| 2025-10-07 | -2.78 |
| 2025-10-06 | -2.78 |
| 2025-10-03 | -2.70 |
| 2025-10-02 | -2.79 |
| 2025-10-01 | -2.66 |
| 2025-09-30 | -2.66 |
| 2025-09-29 | -2.79 |
| 2025-09-26 | -2.61 |
| 2025-09-25 | -2.46 |
| 2025-09-24 | -2.13 |
| 2025-09-23 | -1.95 |
| 2025-09-22 | -2.06 |
| 2025-09-19 | -2.04 |
| 2025-09-18 | -2.06 |
| 2025-09-17 | -1.88 |
| 2025-09-16 | -1.88 |
| 2025-09-15 | -1.82 |
| 2025-09-12 | -1.84 |
| 2025-09-11 | -1.97 |
| 2025-09-10 | -1.97 |
| 2025-09-09 | -1.91 |
| 2025-09-08 | -1.94 |
| 2025-09-05 | -2.04 |
| 2025-09-04 | -1.96 |
| 2025-09-03 | -1.98 |
| 2025-09-02 | -2.01 |
| 2025-08-29 | -1.91 |
| 2025-08-28 | -2.02 |
| 2025-08-27 | -2.00 |